<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T10:02:19Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10122201" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10122201</identifier>
        <datestamp>2023-04-22</datestamp>
        <setSpec>gerosci</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">GeroScience</journal-id>
              <journal-id journal-id-type="iso-abbrev">Geroscience</journal-id>
              <journal-title-group>
                <journal-title>GeroScience</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2509-2715</issn>
              <issn pub-type="epub">2509-2723</issn>
              <publisher>
                <publisher-name>Springer International Publishing</publisher-name>
                <publisher-loc>Cham</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10122201</article-id>
              <article-id pub-id-type="pmcid">PMC10122201</article-id>
              <article-id pub-id-type="pmc-uid">10122201</article-id>
              <article-id pub-id-type="pmid">37086366</article-id>
              <article-id pub-id-type="pmid">37086366</article-id>
              <article-id pub-id-type="publisher-id">794</article-id>
              <article-id pub-id-type="doi">10.1007/s11357-023-00794-6</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Activation of telomerase by TA-65 enhances immunity and reduces inflammation post myocardial infarction</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bawamia</surname>
                    <given-names>Bilal</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Spray</surname>
                    <given-names>Luke</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wangsaputra</surname>
                    <given-names>Vincent K.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bennaceur</surname>
                    <given-names>Karim</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vahabi</surname>
                    <given-names>Sharareh</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stellos</surname>
                    <given-names>Konstantinos</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                  <xref ref-type="aff" rid="Aff6">6</xref>
                  <xref ref-type="aff" rid="Aff7">7</xref>
                  <xref ref-type="aff" rid="Aff8">8</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kharatikoopaei</surname>
                    <given-names>Ehsan</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ogundimu</surname>
                    <given-names>Emmanuel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff9">9</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gale</surname>
                    <given-names>Chris P.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff10">10</xref>
                  <xref ref-type="aff" rid="Aff11">11</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Keavney</surname>
                    <given-names>Bernard</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff12">12</xref>
                  <xref ref-type="aff" rid="Aff13">13</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Maier</surname>
                    <given-names>Rebecca</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hancock</surname>
                    <given-names>Helen</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff14">14</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Richardson</surname>
                    <given-names>Gavin</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff5">5</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Austin</surname>
                    <given-names>David</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                  <xref ref-type="aff" rid="Aff15">15</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2750-2444</contrib-id>
                  <name>
                    <surname>Spyridopoulos</surname>
                    <given-names>Ioakim</given-names>
                  </name>
                  <address>
                    <email>ioakim.spyridopoulos@newcastle.ac.uk</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cdwy346</institution-id><institution-id institution-id-type="GRID">grid.415050.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0641 3308</institution-id><institution>Freeman Hospital, </institution></institution-wrap>Newcastle Upon Tyne, UK </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02vqh3346</institution-id><institution-id institution-id-type="GRID">grid.411812.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0400 2812</institution-id><institution>Academic Cardiovascular Unit, </institution><institution>The James Cook University Hospital, </institution></institution-wrap>Middlesbrough, UK </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kj2bm70</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution>Vascular Biology and Medicine Theme, Faculty of Medical Sciences, International Centre for Life, </institution><institution>Translational and Clinical Research InstituteNewcastle UniversityNewcastle Upon Tyne, </institution></institution-wrap>Central Parkway, NE1 3BZ UK </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/0116zj450</institution-id><institution-id institution-id-type="GRID">grid.9581.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2019 1471</institution-id><institution>Faculty of Medicine, </institution><institution>Universitas Indonesia, </institution></institution-wrap>Central Jakarta, Indonesia </aff>
                <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kj2bm70</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution>Vascular Biology and Medicine Theme, Faculty of Medical Sciences, </institution><institution>Biosciences Institute, Newcastle University, </institution></institution-wrap>Newcastle Upon Tyne, UK </aff>
                <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038t36y30</institution-id><institution-id institution-id-type="GRID">grid.7700.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 4373</institution-id><institution>Department of Cardiovascular Research, European Center for Angioscience (ECAS), </institution><institution>Heidelberg University, </institution></institution-wrap>Mannheim, Germany </aff>
                <aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/031t5w623</institution-id><institution-id institution-id-type="GRID">grid.452396.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 5937 5237</institution-id><institution>German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg/Mannheim, </institution></institution-wrap>Mannheim, Germany </aff>
                <aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/038t36y30</institution-id><institution-id institution-id-type="GRID">grid.7700.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2190 4373</institution-id><institution>Department of Cardiology, </institution><institution>University Hospital Mannheim, Heidelberg University, </institution></institution-wrap>Manheim, Germany </aff>
                <aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01v29qb04</institution-id><institution-id institution-id-type="GRID">grid.8250.f</institution-id><institution-id institution-id-type="ISNI">0000 0000 8700 0572</institution-id><institution>Department of Mathematical Sciences, </institution><institution>Durham University, </institution></institution-wrap>Durham, UK </aff>
                <aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00v4dac24</institution-id><institution-id institution-id-type="GRID">grid.415967.8</institution-id><institution-id institution-id-type="ISNI">0000 0000 9965 1030</institution-id><institution>Department of Cardiology, </institution><institution>Leeds Teaching Hospitals NHS Trust, </institution></institution-wrap>Leeds, UK </aff>
                <aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024mrxd33</institution-id><institution-id institution-id-type="GRID">grid.9909.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8403</institution-id><institution>Leeds Institute for Cardiovascular and Metabolic Medicine, </institution><institution>University of Leeds, </institution></institution-wrap>Leeds, UK </aff>
                <aff id="Aff12"><label>12</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/027m9bs27</institution-id><institution-id institution-id-type="GRID">grid.5379.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 2166 2407</institution-id><institution>Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, </institution><institution>The University of Manchester, </institution></institution-wrap>Manchester, UK </aff>
                <aff id="Aff13"><label>13</label><institution-wrap><institution-id institution-id-type="GRID">grid.498924.a</institution-id><institution-id institution-id-type="ISNI">0000 0004 0430 9101</institution-id><institution>Manchester Heart Institute, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, </institution></institution-wrap>Manchester, UK </aff>
                <aff id="Aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kj2bm70</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution>Newcastle Clinical Trials Unit, Faculty of Medical Sciences, </institution><institution>Newcastle University, </institution></institution-wrap>Newcastle Upon Tyne, UK </aff>
                <aff id="Aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01kj2bm70</institution-id><institution-id institution-id-type="GRID">grid.1006.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0462 7212</institution-id><institution>Population Health Science Institute, Newcastle University, </institution></institution-wrap>Newcastle Upon Tyne, UK </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>22</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>8</month>
                <year>2023</year>
              </pub-date>
              <volume>45</volume>
              <issue>4</issue>
              <fpage>2689</fpage>
              <lpage>2705</lpage>
              <history>
                <date date-type="received">
                  <day>4</day>
                  <month>10</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>6</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2023</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <p id="Par1">Myocardial infarction (MI) accelerates immune ageing characterised by lymphopenia, expansion of terminally differentiated CD8<sup>+</sup> T-lymphocytes (CD8<sup>+</sup> T<sub>EMRA</sub>) and inflammation. Pre-clinical data showed that TA-65, an oral telomerase activator, reduced immune ageing and inflammation after MI. We conducted a double blinded randomised controlled pilot trial evaluating the use of TA-65 to reduce immune cell ageing in patients following MI. Ninety MI patients aged over 65 years were randomised to either TA-65 (16 mg daily) or placebo for 12 months. Peripheral blood leucocytes were analysed by flow cytometry. The pre-defined primary endpoint was the proportion of CD8<sup>+</sup> T-lymphocytes which were CD8<sup>+</sup> T<sub>EMRA</sub> after 12 months. Secondary outcomes included high-sensitivity C-reactive protein (hsCRP) levels. Median age of participants was 71 years. Proportions of CD8<sup>+</sup> T<sub>EMRA</sub> did not differ after 12 months between treatment groups. There was a significant increase in mean total lymphocyte count in the TA-65 group after 12 months (estimated treatment effect: + 285 cells/μl (95% CI: 117–452 cells/ μ l, <italic>p</italic> &lt; 0.004), driven by significant increases from baseline in CD3<sup>+</sup>, CD4<sup>+</sup>, and CD8<sup>+</sup> T-lymphocytes, B-lymphocytes and natural killer cells. No increase in lymphocyte populations was seen in the placebo group. At 12 months, hsCRP was 62% lower in the TA-65 group compared to placebo (1.1 vs. 2.9 mg/L). Patients in the TA-65 arm experienced significantly fewer adverse events (130 vs. 185, <italic>p</italic> = 0.002). TA-65 did not alter CD8<sup>+</sup> T<sub>EMRA</sub> but increased all major lymphocyte subsets and reduced hsCRP in elderly patients with MI after 12 months.
</p>
                <sec>
                  <title>Supplementary Information</title>
                  <p>The online version contains supplementary material available at 10.1007/s11357-023-00794-6.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Acute myocardial infarction</kwd>
                <kwd>Ageing</kwd>
                <kwd>T-lymphocytes</kwd>
                <kwd>Telomerase</kwd>
                <kwd>Immunosenescence</kwd>
              </kwd-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© American Aging Association 2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Introduction</title>
              <p id="Par9">Despite modern advances in therapy, myocardial infarction (MI) still carries a substantial risk of death or recurrent cardiovascular events [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>], and the identification of novel mechanisms and therapeutic targets is therefore urgently needed. We have previously demonstrated that lymphopenia predicts mortality after ST-elevation MI (STEMI) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>], suggesting that premature ageing of the immune system (termed “immunosenescence”) may contribute to poor outcomes.</p>
              <p id="Par10">Immunosenescence is mainly linked to thymic involution and changes in cellular immunity as a response to pathogens, such as recurrent viral infections, throughout life [<xref ref-type="bibr" rid="CR5">5</xref>]. These include a reduction in circulating lymphocytes and naïve T lymphocytes, the loss of stimulatory T lymphocyte co-receptors, the increase of oligoclonal memory cells, and increased levels of pro-inflammatory cytokines [<xref ref-type="bibr" rid="CR6">6</xref>]. Immune ageing has been shown to correlate with higher mortality across different age groups [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Relative lymphopenia in over 50,000 otherwise healthy middle-aged Americans has recently been identified as a strong predictor of overall mortality as well as cardiovascular mortality [<xref ref-type="bibr" rid="CR9">9</xref>]. We have previously shown in the Newcastle 85 + study that women exhibited higher lymphocyte counts together with a higher frequency of naïve T-cells, paralleled by lower cardiovascular mortality without differences in non-cardiovascular mortality [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. In a separate study, we have reported that myocardial infarction (MI) leads to accelerated immunosenescence and shorter leukocyte telomere length [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>].</p>
              <p id="Par11">Lymphocyte proliferation can be enhanced in vitro by activating telomerase, a reverse transcriptase that typically counteracts telomere shortening at the end of chromosomes [<xref ref-type="bibr" rid="CR14">14</xref>]. It has become evident that telomerase is also detectable in differentiated, non-dividing, or low proliferating cells of the cardiovascular system [<xref ref-type="bibr" rid="CR15">15</xref>]. Besides the pivotal role of its catalytic subunit telomerase reverse transcriptase (TERT) in ensuring maintenance of telomere homeostasis, evidence has accumulated demonstrating non-telomeric functions of the enzyme, owing to its localization in mitochondria. TA-65 is an Astragalus root-purified and encapsulated form of cycloastrogenol with increased bioavailability (T.A. Sciences, New York, USA). We have previously shown that TA-65 induces T-lymphocyte proliferation in a TERT-dependent way in vitro [<xref ref-type="bibr" rid="CR16">16</xref>]. Haendeler’s group has recently shown that TA-65 is a mitochondrial rather than nuclear telomerase activator, which depends on the presence of TERT, improving the outcome of mice after experimental myocardial infarction [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
              <p id="Par12">We present the results from the Telomerase ACTivator to reverse Immunosenescence in Acute Coronary Syndrome (TACTIC) trial—the first randomized controlled trial investigating whether treatment with TA-65 for 12 months after MI reduces immune ageing and inflammation.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods</title>
              <sec id="Sec3">
                <title>Trial design and oversight</title>
                <p id="Par13">The TACTIC trial was a single-centre, randomized, double-blind, parallel-group, placebo-controlled phase IIa pilot trial comparing TA-65 with placebo in 90 participants with coronary heart disease who were diagnosed with myocardial infarction in the 6 months prior to enrolment. A total of 90 patients were randomized to either the TA-65 group (<italic>n</italic> = 45) or the placebo group (<italic>n</italic> = 45); TA-65 and placebo were administered as 8 mg doses twice daily for 12 months. The trial was run according to the principles of Good Clinical Practice, and in accordance with all relevant UK legislation and the trial protocol. Written informed consent was obtained from all participants. TACTIC was registered at the International Standard Randomized Controlled Trial Number (ISRCTN) registry (16,613,292) and at the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT), European Union Clinical Trials Register (2017–002,876-26). A favourable ethical opinion was granted on August 18<sup>th</sup> 2018 by the UK Health Research Authority (18/NE/0178). The trial was funded by TA-Sciences Inc (New York, US) as an investigator-led grant to I.S.</p>
              </sec>
              <sec id="Sec4">
                <title>Trial population</title>
                <p id="Par14">Patients were eligible for the trial if they a) were aged 65 years or over with an index presentation of an acute myocardial infarction (either STEMI or NSTEMI) within the previous 6 months, b) had successfully completed revascularisation or were being managed medically following myocardial infarction, c) had evidence of obstructive coronary artery disease on invasive coronary angiography (at least one major epicardial vessel stenosis ≥ 70%), and d) were more than 24 h after presentation with the index event—patients were eligible the following day post percutaneous coronary intervention (PCI) or 3 months after CABG. Exclusion criteria included any condition associated with immunological dysfunction (acute or chronic inflammatory or neoplastic co-existing disease, known positive serology for HIV, or hepatitis); clinical instability (arrhythmias, cardiogenic shock, unconscious); severe, uncontrolled hypertension (Blood Pressure &gt; 170/110 mmHg, or ambulatory BP of 150/95 mmHg); severe comorbidity likely to impact on outcome over the next 2 years, immunosuppressants, known malignancy, patients already taking a nutritional supplement derived from the roots of the Astragalus species, known current or previous substance addiction and insulin-dependent diabetes mellitus.</p>
              </sec>
              <sec id="Sec5">
                <title>Randomization and blinding</title>
                <p id="Par15">Randomisation was performed using a minimisation scheme to ensure patients randomised to each group were comparable at baseline. The minimisation scheme accounted for gender (male or female), type of MI (STEMI or NSTEMI) and proportion of terminally differentiated effector memory CD8<sup>+</sup> T-lymphocytes (CD8<sup>+</sup> T<sub>EMRA</sub>; high &gt; 45% or low ≤ 45%) at baseline. Eligible patients were randomised by delegated and trained members of the research team at the site using a 24-h, central, secure, web-based randomisation system with concealed allocation. Eligible patients were randomised in a 1:1 ratio to receive TA-65 (intervention under study) or placebo (control group). Both groups also received standard NHS care for MI. Assignment to either TA-65 or placebo was blinded to the patient, treating clinicians and the clinical research team (including the pharmacy team), and staff at Newcastle Clinical Trials Unit, except for the data manager. Collection, dispensing and recalling of the drug (TA-65 or placebo) were performed by delegated members of the clinical research team. Study drugs were labelled using a unique identification code that was linked to the study randomisation system. TA-65 and its matched placebo were identical in appearance, smell and taste and presented in the same packaging to ensure blinding of the study drug.</p>
              </sec>
              <sec id="Sec6">
                <title>Outcome measures</title>
                <p id="Par16">The primary outcome measure was the proportion of CD8<sup>+</sup> T-lymphocytes which were terminally differentiated effector memory cells (CD8<sup>+</sup> T<sub>EMRA</sub>; CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup>CCR7<sup>−</sup>CD45RA<sup>+</sup>), measured in peripheral blood with flow cytometry at 12 months. CD8<sup>+</sup> T<sub>EMRA</sub> cells were chosen as a representative parameter for immune ageing, identified among others in the Newcastle 85 + study. [<xref ref-type="bibr" rid="CR10">10</xref>] Secondary outcomes included proportions and absolute counts of other leucocytes subsets, including T-lymphocyte and monocyte subsets, serum levels of high-sensitivity C-reactive protein (hsCRP), telomerase activity, oxidative stress, microvascular endothelial function and cardiac function, assessed by both serum levels of NT-proBNP and transthoracic echocardiography, and adverse events and adverse reactions. hsCRP levels were compared between groups at 12 months. All other secondary outcome measures were analysed as the change from baseline at 12 months.</p>
              </sec>
              <sec id="Sec7">
                <title>Flow-cytometric assays</title>
                <p id="Par17">Two different assays were used for flow cytometric analysis of leucocytes. All measurements were performed on fresh blood within 4 h of collection. There was no significant amount of non-viable cells (&lt; 1%) with this approach. The TruCount assay (containing CD45, CD3, CD4, CD8, CD19, CD16, CD56 fluorochrome-labelled monoclonal antibodies) provided information on the absolute concentration of major leukocyte populations (Fig. <xref rid="Fig1" ref-type="fig">1</xref>), while the 7-colour assay (containing CD3, CD4, CD8, CD45RA, CCR7, CD28, CX3CR1 fluorochrome-labelled monoclonal antibodies) characterised a wider range of receptor expression on these cells (Supplementary Table <xref rid="MOESM1" ref-type="media">S10</xref> and Figure <xref rid="MOESM1" ref-type="media">S1</xref>). By combining the absolute data of the TruCount assay with the relative data of the 7-colour FACS, we defined the size of very specific subpopulations of T-lymphocytes, including the primary outcome measure of CD8<sup>+</sup> T<sub>EMRA</sub>. Full details of both assays are described in the <xref rid="MOESM1" ref-type="media">Supplementary Methods</xref>. Data acquisition was performed with an Analytical Fluoresence Flow Cytometer BD FORTESSA machine using BD FACSDiva software version 8.0.1. The acquisition parameters were set to stop collecting data after 3,000 events of TruCount Beads to ensure accurate enumeration, and 10,000 CD8<sup>+</sup> events for the 7-colour assay, as previously described [<xref ref-type="bibr" rid="CR3">3</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Gating of main leukocyte populations with TruCount assay. Flow cytometric analysis of a representative patient from the TACTIC trial is shown. At first, lymphocytes, monocytes, neutrophils, and beads were gated in SSC-Area against the leukocyte marker CD45. Lymphocytes were sequentially gated into CD3<sup>+</sup> (T cells) and CD3<sup>−</sup> cells. CD4<sup>+</sup> and CD8<sup>+</sup> T cells were gated from CD3 + cells, while B cells (CD19<sup>+</sup>) and natural killer cells (CD19<sup>−</sup>CD16<sup>+</sup>CD56<sup>+</sup>) were gated from CD3<sup>−</sup> cells. Several sub-gates were sequentially gated from the main monocyte population to ensure that gating was performed on specific CD3<sup>−</sup>CD4<sup>+</sup>CD19<sup>−</sup>CD45<sup>+</sup> cells. Finally, monocytes were divided into classical (CLA), intermediate (INT), or non-classical monocytes (NON CLA) based on the abundance of CD16 expression</p></caption><graphic xlink:href="11357_2023_794_Fig1_HTML" id="MO1"/></fig></p>
              </sec>
              <sec id="Sec8">
                <title>Telomerase activity</title>
                <p id="Par18">Nuclear telomerase activity in peripheral blood mononuclear cells (PBMCs) was measured using the Telomerase Repeated Activation Protocol (TRAP) – quantitative polymerase chain reaction (qPCR) assay. Within 24 h of collection, whole blood was centrifuged to isolate PBMCs, which were cryopreserved at − 80 C. The cells were subsequently thawed, lysed, and analysed using a validated TRAP-qPCR protocol (Supplementary Tables <xref rid="MOESM1" ref-type="media">S11</xref> and <xref rid="MOESM1" ref-type="media">S12</xref>), with the human T cell leukaemia line 1301 acting as the positive control (Supplementary Figures <xref rid="MOESM1" ref-type="media">S2</xref> and S3) [<xref ref-type="bibr" rid="CR18">18</xref>]. The full protocol is described in the Supplementary Methods.</p>
              </sec>
              <sec id="Sec9">
                <title>Oxidative stress</title>
                <p id="Par19">Oxidative stress was measured using the TBARS colorimetric assay. This assay is described in detail in the <xref rid="MOESM1" ref-type="media">Supplementary Methods</xref>, but briefly involves the addition of thiobarbituric acid to plasma samples, which in the presence of lipid perioxidation products yield a pink solution, which can be quantified with colorimetry.</p>
              </sec>
              <sec id="Sec10">
                <title>Endothelial function</title>
                <p id="Par20">Endothelial function was evaluated using the EndoPAT device (Itamar Medical Ltd, Caesarea, Israel). This non-invasive operator-independent system consists of finger probes that measures peripheral arterial tone (PAT) for 5 min at rest and during reactive hyperaemia induced by 5-min forearm cuff occlusion. The reactive hyperaemia index (RHI) is the post- to pre- occlusion PAT signal ratio in the occluded arm relative to the same ratio in the control arm. RHI was measured at baseline, 6 months and 12 months (Supplementary Figure <xref rid="MOESM1" ref-type="media">S4</xref>).</p>
              </sec>
              <sec id="Sec11">
                <title>Echocardiography</title>
                <p id="Par21">Transthoracic echocardiography (TTE) was performed at baseline and 12 months to evaluate left ventricular function including global longitudinal strain (<xref rid="MOESM1" ref-type="media">Supplementary Methods</xref>).</p>
              </sec>
              <sec id="Sec12">
                <title>Adverse events</title>
                <p id="Par22">Adverse events (AEs), adverse reactions (ARs), serious adverse events (SAEs), and serious adverse reactions (SARs) were assessed by a medical practitioner for severity and causality. The severity of each was classified as follows: grade 1—minor event not requiring medical intervention, grade 2—an event which is symptomatic and may require medical attention, grade 3—a significant event which requires medical intervention and may require hospitalisation, grade 4—an event that requires urgent medical intervention and is potentially life-threatening, grade 5—death.</p>
              </sec>
              <sec id="Sec13">
                <title>Statistical analysis</title>
                <p id="Par23">Continuous variables were reported by number, mean ± SD, median (IQR) or minimum and maximum, whereas number and percentages summarised categorical variables. The proportion of CD8<sup>+</sup> T<sub>EMRA</sub> was calculated from the total number of peripheral blood CD8<sup>+</sup> T cells in each blood sample, so it was treated as a continuous outcome. Therefore, a linear mixed-effect model assuming Gaussian distribution with adjustment for minimisation factors, trial group and time points (baseline and 12 months) as predictors were used for the primary analysis, using intention-to-treat principles to quantify the change in the proportion of CD8<sup>+</sup> T<sub>EMRA</sub> from baseline to 12 months. Continuous secondary outcomes were analysed using linear mixed-effects models to consider the follow-up time effect and intra-patient correlation. All models accounted for treatment group and stratification variables used in the randomisation scheme. The coefficients and their associated confidence intervals were reported for each predictor included in the models. All hypothesis testing was at 5% significance level. Since there was no sample size calculation, the study was not powered to detect the minimum meaningful change in the primary outcome compared to baseline. Therefore, all efficacy analyses and 95% confidence intervals are for the purpose of guidance and the focus is on the estimated effects rather than their statistical significance. All analyses were done on a PC running Microsoft Windows 10, and the statistical programming code R was used for the analysis.</p>
              </sec>
            </sec>
            <sec id="Sec14">
              <title>Results</title>
              <sec id="Sec15">
                <title>Trial progress</title>
                <p id="Par24">All patients were recruited at The James Cook University Hospital, Middlesbrough, UK, between 21<sup>st</sup> January 2019 and 17<sup>th</sup> March 2020. The final trial visit was performed on 18<sup>th</sup> March 2021. Of 310 patients assessed for eligibility, 90 patients were randomised to placebo (<italic>n</italic> = 45) or TA-65 (<italic>n</italic> = 45; Fig. <xref rid="Fig2" ref-type="fig">2</xref>) and all underwent primary outcome sample analyses at baseline. No patients were lost to follow up; 15 patients (7 from placebo group and 8 from TA-65) discontinued trial medications (Supplemental Table <xref rid="MOESM1" ref-type="media">S1</xref>) and of those, 7 attended for primary outcome sample analyses at 12 months. Due to COVID-19 related trial visit restrictions, 20 patients (10 in each group) continued trial medication for 15 months to allow measurement of final endpoints when national restrictions were lifted. 37 patients in each group of the study were adherent to treatment (pre-defined as &gt; 80% of doses taken over the study period).<fig id="Fig2"><label>Fig. 2</label><caption><p>Consolidated Standards of Reporting Trials (CONSORT) diagram of patient enrolment. The diagram shows the number of patients who met the inclusion or exclusion criteria and their distribution among the two study groups. TA-65 and placebo were administered as 8-mg doses twice daily for 12 months</p></caption><graphic xlink:href="11357_2023_794_Fig2_HTML" id="MO2"/></fig></p>
              </sec>
              <sec id="Sec16">
                <title>Baseline characteristics</title>
                <p id="Par25">The median age of participants was 71 years and 16.7% were women (Table <xref rid="Tab1" ref-type="table">1</xref>). All participants were of white ethnicity. There was a higher percentage of smokers or ex-smokers in the placebo group (82.2% vs 62.2%, <italic>p</italic> = 0.04). Both groups were otherwise well balanced with regards to baseline patient, treatment and MI characteristics. The index coronary event was NSTEMI in 52.2% and STEMI in 47.8%, and 86.7% were treated with PCI. There were 14 (31.1%) anterior infarcts in each group. Procedural characteristics are reported in Supplemental Table <xref rid="MOESM1" ref-type="media">S2</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of baseline demographics, past medical history, medications and MI characteristics between treatment groups. Continuous and categorical variables were compared using simple linear regression and logistic regression analyses respectively</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Placebo (<italic>n</italic> = 45)</th><th align="left">TA-65 (<italic>n</italic> = 45)</th><th align="left"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left">Baseline demographics</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Age, mean (SD), y</td><td align="left">72 (4.79)</td><td align="left">71.6 (4.83)</td><td align="left">0.73</td></tr><tr><td align="left">Male sex, n (%)</td><td align="left">38 (84.4)</td><td align="left">37 (82.2)</td><td align="left">0.78</td></tr><tr><td align="left">Current or ex-smoker, n (%)</td><td align="left">37 (82.2)</td><td align="left">28 (62.2)</td><td align="left">0.04</td></tr><tr><td align="left">Past medical history, n (%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Atrial fibrillation or flutter</td><td align="left">6 (13.3)</td><td align="left">1 (2.2)</td><td align="left">0.08</td></tr><tr><td align="left">Hypertension</td><td align="left">21 (46.7)</td><td align="left">24 (53.3)</td><td align="left">0.53</td></tr><tr><td align="left">Hyperlipidaemia</td><td align="left">33 (73.3)</td><td align="left">25 (55.6)</td><td align="left">0.08</td></tr><tr><td align="left">Type 2 diabetes mellitus</td><td align="left">5 (11.1)</td><td align="left">8 (17.8)</td><td align="left">0.37</td></tr><tr><td align="left">Previous MI</td><td align="left">11 (24.4)</td><td align="left">5 (11.1)</td><td align="left">0.11</td></tr><tr><td align="left">Previous PCI</td><td align="left">6 (13.3)</td><td align="left">7 (15.6)</td><td align="left">0.76</td></tr><tr><td align="left">Previous CABG</td><td align="left">6 (13.3)</td><td align="left">2 (4.4)</td><td align="left">0.16</td></tr><tr><td align="left">PVD</td><td align="left">2 (4.4)</td><td align="left">4 (8.9)</td><td align="left">0.41</td></tr><tr><td align="left">Previous TIA or CVA</td><td align="left">5 (11.1)</td><td align="left">2 (4.4)</td><td align="left">0.25</td></tr><tr><td align="left">CMV seropositive</td><td align="left">34 (75.6)</td><td align="left">31 (68.9)</td><td align="left">0.48</td></tr><tr><td align="left">Baseline medications, n (%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Aspirin</td><td align="left">45 (100)</td><td align="left">45 (100)</td><td align="left">1</td></tr><tr><td align="left">Clopidogrel</td><td align="left">8 (18)</td><td align="left">6 (13)</td><td align="left">0.43</td></tr><tr><td align="left">Ticagrelor</td><td align="left">36 (80)</td><td align="left">38 (84)</td><td align="left">1</td></tr><tr><td align="left">Prasugrel</td><td align="left">0 (0)</td><td align="left">1 (2)</td><td align="left">1</td></tr><tr><td align="left">Statin</td><td align="left">44 (98)</td><td align="left">45 (100)</td><td align="left">0.99</td></tr><tr><td align="left">ACE-inhibitor/ARB</td><td align="left">43 (96)</td><td align="left">43 (96)</td><td align="left">1</td></tr><tr><td align="left">Clinical measurements, mean (SD)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Systolic BP, mmHg</td><td align="left">119 (17)</td><td align="left">123 (17)</td><td align="left">0.33</td></tr><tr><td align="left">Diastolic BP, mmHg</td><td align="left">72 (11)</td><td align="left">72 (10)</td><td align="left">0.93</td></tr><tr><td align="left">Glucose, mmol/L</td><td align="left">6.8 (1.5)</td><td align="left">7.1 (2.3)</td><td align="left">0.48</td></tr><tr><td align="left">Total cholesterol, mmol/L</td><td align="left">4.5 (1.2)</td><td align="left">4.4 (1.3)</td><td align="left">0.61</td></tr><tr><td align="left">LDL-C, mmol/L</td><td align="left">2.5 (1.2)</td><td align="left">2.6 (1.1)</td><td align="left">0.63</td></tr><tr><td align="left">HDL-C, mmol/L</td><td align="left">1.3 (0.7)</td><td align="left">1.1 (0.3)</td><td align="left">0.16</td></tr><tr><td align="left">LVEF, %</td><td align="left">52.2 (11.4)</td><td align="left">55.7 (10.7)</td><td align="left">0.14</td></tr><tr><td align="left">MI characteristics</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Type of MI, n (%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">NSTEMI</td><td align="left">23 (51.1)</td><td align="left">24 (53.3)</td><td align="left">-</td></tr><tr><td align="left">STEMI</td><td align="left">22 (48.9)</td><td align="left">21 (46.7)</td><td align="left">0.83</td></tr><tr><td align="left">Anterior infarct (vs Non- Anterior), n (%)</td><td align="left">14 (31.1)</td><td align="left">14 (31.1)</td><td align="left">1</td></tr><tr><td align="left">MI treatment, n (%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">PCI</td><td align="left">41 (91.1)</td><td align="left">37 (82.2)</td><td align="left">-</td></tr><tr><td align="left">Medical (vs PCI)</td><td align="left">4 (8.9)</td><td align="left">6 (13.3)</td><td align="left">0.80</td></tr><tr><td align="left">CABG (vs PCI)</td><td align="left">0 (0)</td><td align="left">2 (4.4)</td><td align="left">0.46</td></tr><tr><td align="left">No. of vessel disease, n (%)</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">One</td><td align="left">26 (57.8)</td><td align="left">22 (48.9)</td><td align="left">-</td></tr><tr><td align="left">Two (vs One)</td><td align="left">16 (35.6)</td><td align="left">15 (33.3)</td><td align="left">0.82</td></tr><tr><td align="left">Three (vs One)</td><td align="left">3 (6.7)</td><td align="left">8 (17.8)</td><td align="left">0.12</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation, <italic>MI</italic> myocardial infarction, <italic>PCI</italic> percutaneous coronary intervention, <italic>CABG</italic> coronary artery bypass graft, <italic>PVD</italic> peripheral vascular disease, <italic>TIA</italic> transient ischemic attack, <italic>CVA</italic> cerebrovascular accident, <italic>CMV</italic> cytomegalovirus, <italic>ACE</italic> angiotensin-converting enzyme, <italic>ARB</italic> angiotensin receptor blocker, <italic>BP</italic> blood pressure, <italic>LDL-C</italic> low-density lipoprotein cholesterol, <italic>HDL-C</italic> high-density lipoprotein cholesterol, <italic>LVEF</italic> left ventricular ejection fraction, <italic>NSTEMI</italic> non ST segment elevation myocardial infarction, <italic>STEMI</italic> ST segment elevation myocardial infarction</p></table-wrap-foot></table-wrap></p>
              </sec>
              <sec id="Sec17">
                <title>Effect on primary study endpoint and other leukocyte populations</title>
                <p id="Par26">The primary endpoint of the trial, the proportion of CD8<sup>+</sup> T-lymphocytes which were CD8<sup>+</sup> T<sub>EMRA</sub>, did not differ between the 2 groups after 12 months (Table <xref rid="Tab2" ref-type="table">2</xref>). The proportion of CD8<sup>+</sup> T<sub>EMRA</sub> cells did not change significantly after 6 and 12 months in both groups. The proportion of CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets remained similar in each treatment group throughout the duration of the trial and this finding was consistent in both STEMI and NSTEMI subgroups (Supplementary Table <xref rid="MOESM1" ref-type="media">S3</xref> and <xref rid="MOESM1" ref-type="media">S4</xref>). We observed a substantial, absolute increase in total lymphocyte count only in the TA-65 group (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). This was driven by significant increase in CD4<sup> +</sup> , CD8<sup>+</sup> , B-lymphocytes and natural killer cells (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B–F). In contrast, there were no changes in neutrophils and monocytes counts (Fig. <xref rid="Fig3" ref-type="fig">3</xref>G–H). The treatment effect on total lymphocyte count was estimated as + 285 cells/μl (95% CI: 117–452 cells/μl, <italic>p</italic> &lt; 0.004) (Supplementary Table <xref rid="MOESM1" ref-type="media">S5</xref>). Interestingly, this was significant in NSTEMI but not STEMI subgroups (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The median times (range) from MI onset to baseline blood sampling in STEMI and NSTEMI were 3 (2–111) and 19 (2–134) days respectively.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Comparison of the proportion of CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes as a percentage of parent population identified as each of four subsets by flow cytometry between placebo and TA-65 is shown at baseline, 6 months and 12 months. Results are shown as the mean value (standard deviation) for each treatment arm at each time point. A linear mixed-effect model was used to quantify the change in the proportion from baseline to 12 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"/><th align="left" colspan="2">Placebo</th><th align="left"/><th align="left" colspan="2">TA-65</th><th align="left" rowspan="2">12-month Treatment effect</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left"/><th align="left">Baseline<break/>Mean (SD)</th><th align="left">6 months<break/>Mean (SD)</th><th align="left">12 months<break/>Mean (SD)</th><th align="left">Baseline<break/>Mean (SD)</th><th align="left">6 months<break/>Mean (SD)</th><th align="left">12 months<break/>Mean (SD)</th></tr></thead><tbody><tr><td align="left">CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup></td><td align="left">24.1 (14.3)</td><td align="left">20.9 (11.4)</td><td align="left">20.1 (10.2)</td><td align="left">26.9 (15.2)</td><td align="left">26.1 (16.4)</td><td align="left">24.4 (14.0)</td><td align="left">-0.2 (-2.6, 2.2)</td><td char="." align="char">0.86</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup> Terminally differentiated effector memory <italic>(primary endpoint)</italic></td><td align="left">59.1 (19.3)</td><td align="left">59.0 (18.5)</td><td align="left">61.0 (19.8)</td><td align="left">58.1 (21.7)</td><td align="left">64.3 (18.7)</td><td align="left">60.8 (21.0)</td><td align="left">-0.3 (-4.1, 3.4)</td><td char="." align="char">0.86</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup> Naive</td><td align="left">7.2 (6.1)</td><td align="left">5.9 (4.3)</td><td align="left">5.9 (4.0)</td><td align="left">6.9 (5.1)</td><td align="left">6.4 (4.5)</td><td align="left">6.2 (4.4)</td><td align="left">0.4 (-1.4, 2.2)</td><td char="." align="char">0.65</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup> Central memory</td><td align="left">11.5 (7.5)</td><td align="left">11.3 (7.0)</td><td align="left">11.1 (7.8)</td><td align="left">12.1 (9.8)</td><td align="left">10.4 (7.7)</td><td align="left">11.0 (8.4)</td><td align="left">-0.7 (-2.5,1.1)</td><td char="." align="char">0.43</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>−</sup>CD8<sup>+</sup> Effector memory</td><td align="left">22.1 (11.8)</td><td align="left">23.8 (12.0)</td><td align="left">22.0 (12.0)</td><td align="left">22.9 (15.2)</td><td align="left">18.9 (11.5)</td><td align="left">21.9 (16.0)</td><td align="left">0.7 (-2.5, 3.8)</td><td char="." align="char">0.69</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup></td><td align="left">64.3 (14.7)</td><td align="left">66.5 (12.7)</td><td align="left">66.0 (12.7)</td><td align="left">61.1 (14.8)</td><td align="left">59.8 (16.2)</td><td align="left">61.9 (15.1)</td><td align="left">0.9 (-1.7,3.5)</td><td char="." align="char">0.49</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup> Terminally differentiated effector memory</td><td align="left">2.6 (3.8)</td><td align="left">2.3 (3.3)</td><td align="left">2.6 (4.3)</td><td align="left">3.6 (6.7)</td><td align="left">3.6 (7.3)</td><td align="left">3.6 (8.1)</td><td align="left">0.2 (-0.5, 0.8)</td><td char="." align="char">0.60</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup> Naive</td><td align="left">42.3 (14.3)</td><td align="left">45.2 (15.0)</td><td align="left">46.9 (14.2)</td><td align="left">40.0 (15.9)</td><td align="left">41.8 (15.0)</td><td align="left">44.6 (15.5)</td><td align="left">0.8 (-2.5,4.1)</td><td char="." align="char">0.63</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup> Central memory</td><td align="left">42.7 (13.0)</td><td align="left">41.5 (13.0)</td><td align="left">39.8 (13.9)</td><td align="left">42.4 (14.6)</td><td align="left">42.8 (14.1)</td><td align="left">41.3 (13.9)</td><td align="left">-0.5 (-3.0,2.0)</td><td char="." align="char">0.7</td></tr><tr><td align="left">CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>−</sup> Effector memory</td><td align="left">12.3 (6.9)</td><td align="left">10.9 (6.4)</td><td align="left">10.6 (5.9)</td><td align="left">14.0 (13.7)</td><td align="left">11.7 (9.5)</td><td align="left">10.5 (9.0)</td><td align="left">-0.5 (-2.0,1.0)</td><td char="." align="char">0.5</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation</p></table-wrap-foot></table-wrap><fig id="Fig3"><label>Fig. 3</label><caption><p>Comparison of absolute leukocyte counts (Cells/μL from Trucount assay) between TA-65 and placebo treated patients at baseline, 6 months and 12 months. (A) Total lymphocytes. (B) T-lymphocytes. (C) CD4<sup>+</sup> T-lymphocytes. (D) CD8<sup>+</sup> T-lymphocytes. (E) B-lymphocytes. (F) Natural Killer (NK) cells. (G) Neutrophils. (H) Monocytes.(A)–(H): Patients on TA-65 are depicted with red squares (<italic>n</italic> = 45 at baseline, <italic>n</italic> = 37 at 6 m, <italic>n</italic> = 40 at 12 m) and placebo-treated patients with blue circles (<italic>n</italic> = 45 at baseline, <italic>n</italic> = 36 at 6 m, <italic>n</italic> = 42 at 12 m). All time points are shown as mean ± standard error of mean. We performed two different statistical tests: a) 6 month and 12 month time points in each treatment arm were compared against baseline value and <italic>p</italic> value placed next to related data point using linear regression model (* is <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, and *** <italic>p</italic> &lt; 0.004), b) p value for treatment effect TA-65 vs. placebo after 12 months is stated next to bracket of 12 month data points using a mixed-effect linear model assuming Gaussian distribution for the error term</p></caption><graphic xlink:href="11357_2023_794_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Comparison of absolute leukocyte populations (Cells/μL from Trucount assay) between TA-65 and placebo treated patients stratified to MI type at baseline and 12 months. (<bold>A</bold>) Total lymphocytes. (<bold>B</bold>) T-lymphocytes. (C) CD4<sup>+</sup> T-lymphocytes. (<bold>D</bold>) CD8<sup>+</sup> T-lymphocytes. (<bold>E</bold>) B-lymphocytes. (<bold>F</bold>) Natural Killer (NK) cells. (<bold>G</bold>) Neutrophils. (<bold>H</bold>) Monocytes. (<bold>A</bold>)–(<bold>H</bold>): Patients on TA-65 are depicted with red squares and placebo-treated patients with blue circles (left: STEMI <italic>n</italic> = 22 at baseline, <italic>n</italic> = 22 at 12 m, right: NSTEMI <italic>n</italic> = 21 at baseline, <italic>n</italic> = 20 at 12 m). All time points are shown as mean ± standard error of mean. P value for treatment effect TA-65 vs. placebo after 12 months is stated next to bracket using a mixed-effect linear model assuming Gaussian distribution for the error term. STEMI = ST-elevation myocardial infarction. NSTEMI = non-ST elevation myocardial infarction</p></caption><graphic xlink:href="11357_2023_794_Fig4_HTML" id="MO4"/></fig></p>
              </sec>
              <sec id="Sec18">
                <title>Effect of TA-65 on high-sensitivity C-reactive protein</title>
                <p id="Par27">High-sensitivity C-reactive protein (hsCRP) levels were used as a surrogate for systemic inflammation and were similar in TA-65 and placebo groups at baseline (11.9 vs 10.9 mg/L). At 12 months, however, hsCRP levels in patients taking TA-65 were 62.1% lower than in those taking placebo (1.1 vs 2.9 mg/L). After 12 months, the treatment effect of TA-65 in change in hsCRP was estimated to be -2.9 mg/L (95% CI for treatment effect: -12.1–6.2, <italic>p</italic> = 0.53; Table <xref rid="Tab3" ref-type="table">3</xref>). As expected, STEMI patients had higher baseline levels of hsCRP (17.9 and 18.1 mg/L for TA-65 and placebo, respectively) than NSTEMI patients (6.7 and 4.4 mg/L). In a subgroup analysis, mean hsCRP value in STEMI patients at 12 months was 71.8% lower in the TA-65 group compared to placebo (1.1 vs 3.9 mg/L); in NSTEMI patients, this was 45.0% lower (1.1 vs 2.0 mg/L) (Fig. <xref rid="Fig5" ref-type="fig">5</xref>). These numerical differences were not statistically significant after 12 months compared to baseline, possibly due to the low sample sizes in the subgroups. We also observed an interesting trend in the TA-65 group, where each increase in lymphocyte count of 100 cells per microliter, or 0.1 × 10<sup>9</sup>/mL, correlated with a 0.95 mg/L greater decrease in hsCRP between baseline and 12 months, although this correlation was not statistically significant (95% CI: − 2.28–0.42) (Supplemental Table <xref rid="MOESM1" ref-type="media">S6</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Comparison of Telomerase activity, oxidative stress, endothelial function as determined by RHI and NT pro-BNP between placebo and TA-65 is shown at baseline, 6 months and 12 months. Results are shown as the mean value (standard deviation) for each treatment arm at each time point. Secondary outcomes were analysed using linear mixed-effects models to consider the follow-up time effect and intra-patient correlation. The treatment effect represents the change in outcome due to treating with TA-65 vs placebo at 12 months</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="3">Placebo</th><th align="left" colspan="3">TA-65</th><th align="left" rowspan="2">12-months Treatment effect</th><th align="left" rowspan="2"><italic>P</italic>-value</th></tr><tr><th align="left"/><th align="left">Baseline<break/>Mean (SD)</th><th align="left">6 months<break/>Mean (SD)</th><th align="left">12 months<break/>Mean (SD)</th><th align="left">Baseline<break/>Mean (SD)</th><th align="left">6 months<break/>Mean (SD)</th><th align="left">12 months<break/>Mean (SD)</th></tr></thead><tbody><tr><td align="left" rowspan="2">Telomerase</td><td align="left">N = 41</td><td align="left">N = 36</td><td align="left">N = 33</td><td align="left">N = 42</td><td align="left">N = 36</td><td align="left">N = 34</td><td align="left" rowspan="2">-4.8 (-160.2,151.1)</td><td align="left" rowspan="2">0.95</td></tr><tr><td align="left">540.6 (378.9)</td><td align="left">559.4 (332.1)</td><td align="left">552.1 (269.0)</td><td align="left">524.8 (306.1)</td><td align="left">538.2 (347.2)</td><td align="left">541.7 (283.3)</td></tr><tr><td align="left" rowspan="2">Oxidative stress</td><td align="left">N = 41</td><td align="left">N = 35</td><td align="left">N = 41</td><td align="left">N = 38</td><td align="left">N = 34</td><td align="left">N = 39</td><td align="left" rowspan="2">0.08 (-0.11,0.26)</td><td align="left" rowspan="2">0.42</td></tr><tr><td align="left">0.69 (0.34)</td><td align="left">0.70 (0.40)</td><td align="left">0.60 (0.39)</td><td align="left">0.72 (0.41)</td><td align="left">0.77 (0.36)</td><td align="left">0.70 (0.36)</td></tr><tr><td align="left" rowspan="2">Endothelial function (RHI)</td><td align="left">N = 45</td><td align="left">N = 35</td><td align="left">N = 37</td><td align="left">N = 44</td><td align="left">N = 37</td><td align="left">N = 39</td><td align="left" rowspan="2">0.03 (-0.23,0.30)</td><td align="left" rowspan="2">0.82</td></tr><tr><td align="left">1.85 (0.51)</td><td align="left">1.73 (0.49)</td><td align="left">1.82 (0.51)</td><td align="left">1.93 (0.53)</td><td align="left">1.87 (0.35)</td><td align="left">1.95 (0.64)</td></tr><tr><td align="left" rowspan="2">hsCRP, mg/L</td><td align="left">N = 42</td><td align="left">N = 36</td><td align="left">N = 42</td><td align="left">N = 43</td><td align="left">N = 36</td><td align="left">N = 40</td><td align="left" rowspan="2">-2.9 (-12.1,6.2)</td><td align="left" rowspan="2">0.53</td></tr><tr><td align="left">10.9 (23.9)</td><td align="left">3.4 (9.9)</td><td align="left">2.9 (6.5)</td><td align="left">11.9 (25.7)</td><td align="left">1.7 (2.4)</td><td align="left">1.1 (0.9)</td></tr><tr><td align="left" rowspan="2">NTproBNP, pg/mL</td><td align="left">N = 45</td><td align="left">N = 36</td><td align="left">N = 42</td><td align="left">N = 45</td><td align="left">N = 36</td><td align="left">N = 40</td><td align="left" rowspan="2">-302.9 (-746.2, 141.8)</td><td align="left" rowspan="2">0.19</td></tr><tr><td align="left">947.4 (1084.5)</td><td align="left">262.1 (302.7)</td><td align="left">519.9 (1439.1)</td><td align="left">988.1 (1408.6)</td><td align="left">277.1 (328.8)</td><td align="left">299.1 (348.8)</td></tr></tbody></table><table-wrap-foot><p><italic>SD</italic> standard deviation, <italic>RHI</italic> reactive hyperaemic index, <italic>CRP</italic> C-reactive protein, <italic>NTproBNP</italic> N-terminal pro B-type natriuretic peptide</p></table-wrap-foot></table-wrap><fig id="Fig5"><label>Fig. 5</label><caption><p>Comparison of mean hsCRP (mg/L) between TA-65 and placebo treated patients stratified to MI type at baseline, 6 months and 12 months. hsCRP is shown using a logarithmic scale. Patients on TA-65 are depicted with red squares and placebo-treated patients with blue circles. Left: STEMI patients (<italic>n</italic> = 20 at baseline, <italic>n</italic> = 17 at 6 m, <italic>n</italic> = 20 at 12 m), and to the right NSTEMI patients (<italic>n</italic> = 22 at baseline, <italic>n</italic> = 19 at 6 m, <italic>n</italic> = 20 at 12 m). All time points are shown as mean ± standard error of mean. We performed two different statistical tests: 6 month and 12 month time points in each treatment arm were compared against baseline value and <italic>p</italic> value placed next to related data point using linear regression model (* is <italic>p</italic> &lt; 0.05, ** <italic>p</italic> &lt; 0.01, and *** <italic>p</italic> &lt; 0.004), b) <italic>p</italic> value for treatment effect TA-65 vs. placebo after 12 months is stated next to bracket of 12 month data points using a mixed-effect linear model assuming Gaussian distribution for the error term. CRP = C-reactive protein, STEMI = ST-elevation myocardial infarction. NSTEMI = non-ST elevation myocardial infarction</p></caption><graphic xlink:href="11357_2023_794_Fig5_HTML" id="MO5"/></fig></p>
              </sec>
              <sec id="Sec19">
                <title>Effect on telomerase activity and oxidative stress</title>
                <p id="Par28">Nuclear telomerase activity did not change significantly between baseline and 12 months in either group. The estimated change after 12 months in telomerase activity was + 22.9 (95% CI − 91.8–136.0) in the placebo group, and + 18.5 (95% CI: − 89.4–125.9) in the TA-65 group (Table <xref rid="Tab3" ref-type="table">3</xref>). Overall, there was no treatment effect at 12 months compared to baseline (− 4.8, 95% CI: − 160.2–151.1, <italic>p</italic> = 0.95). Treatment with TA-65 after 12 months also did not impact on oxidative stress (estimated treatment effect at 12 months compared to baseline: + 0.08, 95% CI: − 0.11–0.26, <italic>p</italic> = 0.42).</p>
              </sec>
              <sec id="Sec20">
                <title>Effect on endothelial function and cardiac function</title>
                <p id="Par29">There were no significant treatment effects of TA-65 on reactive hyperaemic index after 6 or 12 months compared to baseline (Table <xref rid="Tab3" ref-type="table">3</xref>). NT-proBNP, a biochemical marker of ventricular stretch, reduced from 988 to 299 pg/mL after 12 months (69.7% reduction) in the TA-65 group. A smaller reduction of 45.1% was seen in the placebo group (947 to 520 pg/mL), although the treatment effect of TA-65 after 12 months was not statistically significant (Table <xref rid="Tab3" ref-type="table">3</xref>). After 12 months of treatment, there were no significant treatment effects of TA-65 with respect to LV end diastolic volume, LV ejection fraction or peak systolic global longitudinal strain (Supplemental table <xref rid="MOESM1" ref-type="media">S7</xref>).</p>
              </sec>
              <sec id="Sec21">
                <title>Adverse events and clinical outcomes</title>
                <p id="Par30">There were 315 adverse events reported, with significantly fewer in the TA-65 group compared to placebo (130 vs 185, <italic>p</italic> = 0.002) (Table <xref rid="Tab4" ref-type="table">4</xref>). Most AEs were grade 1 (49.5%) or grade 2 (36.5%); most common were infectious, gastrointestinal or respiratory events (Supplemental Table <xref rid="MOESM1" ref-type="media">S8</xref>). Only three AEs were possibly related to trial medication (six AEs possibly related to trial medication; Supplemental Table <xref rid="MOESM1" ref-type="media">S9</xref>). The number of serious AEs was similar in TA-65 and placebo groups (19 vs 23); no SAEs were related to the trial medication. Fewer patients reported any grade 1–3 adverse effects in the TA-65 group (Supplemental Table <xref rid="MOESM1" ref-type="media">7</xref>). One patient had a grade 4 AE (respiratory failure, which resolved) and one patient died of acute myeloid leukaemia—both in the TA-65 group but were unrelated to treatment.<table-wrap id="Tab4"><label>Table 4</label><caption><p>Comparison of adverse events severity between treatment groups. Total number of adverse events compared between groups using Poisson regression. Percentages given in placebo and TA-65 columns are as proportion of all AEs of that grade. Percentage given in Total column are as percentage of all AEs. Definition of severity grade is given in the main text</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Adverse Event Severity</th><th align="left">Placebo</th><th align="left">TA-65</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left"><p>All Adverse Events</p><p>(Grade 1–5)</p></td><td align="left">185 (58.7%)</td><td align="left">130 (41.3%)</td><td align="left"><p>315</p><p>(<italic>p</italic> = 0.002)</p></td></tr><tr><td align="left">Grade 1</td><td align="left">91 (58.3%)</td><td align="left">65 (41.7%)</td><td align="left">156 (49.5%)</td></tr><tr><td align="left">Grade 2</td><td align="left">71 (61.7%)</td><td align="left">44 (38.3%)</td><td align="left">115 (36.5%)</td></tr><tr><td align="left">Grade 3</td><td align="left">23 (54.8%)</td><td align="left">19 (45.2%)</td><td align="left">42 (13.3%)</td></tr><tr><td align="left">Grade 4</td><td align="left">0</td><td align="left">1 (100%)</td><td align="left">1 (0.3%)</td></tr><tr><td align="left">Grade 5</td><td align="left">0</td><td align="left">1 (100%)</td><td align="left">1 (0.3%)</td></tr></tbody></table><table-wrap-foot><p><italic>AE</italic> adverse event</p></table-wrap-foot></table-wrap></p>
              </sec>
            </sec>
            <sec id="Sec22">
              <title>Discussion</title>
              <p id="Par31">In this novel clinical trial investigating TA-65 versus placebo in patients aged 65 years and over following myocardial infarction, we established four main results: there was no significant change in senescence-like CD8<sup>+</sup> T<sub>EMRA</sub> after 12 months (the primary end point); there was a significant increase in lymphocytes across all major subpopulations; TA-65 was well tolerated overall with a lower number of total adverse events; there was also a trend towards less inflammation at 12 months. In brief, TA-65 is a treatment that might reduce inflammation while enhancing adaptive immunity following MI.</p>
              <sec id="Sec23">
                <title>Reversal of lymphopenia under TA-65</title>
                <p id="Par32">We demonstrated that TA-65 led to a reversal of relative lymphopenia. This was notable in NSTEMI but not STEMI patients. In STEMI, baseline lymphocytes are elevated between 24 and 72 h post reperfusion [<xref ref-type="bibr" rid="CR3">3</xref>], and thereby may mask a relative increase with TA-65. The precise mechanism by which TA-65 elicits an increase in lymphocytes, paralleled by a decrease in inflammation, is unclear. TA-65 did not increase any specific lymphocyte subsets, such as T cells (increased thymus production/emigration) or B cells (enhanced emigration from bone marrow). In fact, there was no increase even in specific T cell subsets. If the treatment effect of TA-65 was due to enhanced proliferation, and therefore nuclear telomerase activation, we would expect specific subpopulations such as CD8<sup>+</sup>CD57<sup>-</sup> to respond much stronger than their CD8<sup>+</sup>CD57<sup>+</sup>counterparts [<xref ref-type="bibr" rid="CR19">19</xref>]. However, since naïve CD8<sup>+</sup> cells (which are entirely CD57<sup>−</sup>) and CD8 TEMRA (or CD57<sup>+</sup> subsets that are phenotypically CD28<sup>−</sup>CX3CR1<sup>+</sup>) seem to not differ in their response to TA-65, we believe that the underlying mechanism must be a different one. We have previously shown that TA-65 leads to enhanced proliferation in human and mouse T cells, but this study assessed higher doses in vitro than we would expect to generate in vivo with TA-65MD [<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              </sec>
              <sec id="Sec24">
                <title>Mitochondrial dysfunction in T cells as a driver of senescence and inflammageing</title>
                <p id="Par33">Senescence can be driven directly by mitochondrial dysfunction [<xref ref-type="bibr" rid="CR20">20</xref>]. In fact, the mitochondrial function of various cell types, including T cells, has been shown recently to decline with increased age [<xref ref-type="bibr" rid="CR21">21</xref>]. Callender and coworkers have shown that higher mitochondrial mass protects from senescence in CD4<sup>+</sup> T cells, [<xref ref-type="bibr" rid="CR22">22</xref>] while inhibiting mitochondrial function with rotenone generates a senescent CD8<sup>+</sup> T cell phenotype, which is known to be cytotoxic and pro-inflammatory. In vivo, T cells with dysfunctional mitochondria accelerate senescence in mice, leading to a premature ageing phenotype triggered by the induction of proinflammatory cytokines (inflammageing) [<xref ref-type="bibr" rid="CR23">23</xref>]. Senescence accumulation has been demonstrated to induce phenotypic changes in multiple cell populations associated with cardiovascular diseases, including myocardial dysfunction, atherosclerosis and hypertension [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Recent evidence suggests that senescence is not simply a response to this disease but rather contributes to their initiation and progression, as reduction of senescence is associated with the delay, prevention, or reversal of characteristics in a variety of CVDs [<xref ref-type="bibr" rid="CR24">24</xref>–<xref ref-type="bibr" rid="CR27">27</xref>]. Mitochondria are necessary for the expression of the senescence-associated secretory phenotype, a pro-inflammatory cocktail by which senescent cells contribute to disease pathophysiology, directly linking mitochondrial metabolism to pro-inflammatory cellular responses [<xref ref-type="bibr" rid="CR28">28</xref>]. As such, activation of mitochondrial TERT and improved mitochondrial function may contribute to attenuated senescence-associated secretory phenotype (SASP) production and in part explain our observations of reduced inflammation in the TA-65 treated cohort.</p>
              </sec>
              <sec id="Sec25">
                <title>Mitochondrial telomerase activation as a potential mechanism of TA-65</title>
                <p id="Par34">Although there is no direct evidence to suggest that mitochondrial Tert protects against senescence induction, global TERT activation inhibits senescence [<xref ref-type="bibr" rid="CR29">29</xref>] and mitochondrial TERT binds to and protects mitochondrial DNA, which might help to maintain proper electron transport chain function decreasing mitochondrial reactive oxygen species (ROS), a key inducer of senescence [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. Ale-Agha et al. demonstrated the effect of TA-65 on mitochondrial, but not nuclear, telomerase and showed that mitochondrial TERT reduced infarct size after experimental MI in mice [<xref ref-type="bibr" rid="CR17">17</xref>]. Mitochondria are necessary for the expression of SASP, a pro-inflammatory cocktail by which senescent cells contribute to disease pathophysiology, directly linking mitochondrial metabolism to pro-inflammatory cellular responses [<xref ref-type="bibr" rid="CR28">28</xref>]. As such, activation of mitochondrial TERT and improved mitochondrial function may contribute to attenuated SASP production, and in part explain our observations of reduced inflammation in the TA-65 treated cohort [<xref ref-type="bibr" rid="CR31">31</xref>]. Further high-resolution immunophenotyping, such as through spectral or mass cytometry, needs to be carried out to unravel a potential mechanistic link between the increase in lymphocyte populations and reduction in inflammation [<xref ref-type="bibr" rid="CR32">32</xref>]. Hence, we speculate that TA-65 is a mitochondrial telomerase activator and enhances mitochondrial function to reduce inflammation [<xref ref-type="bibr" rid="CR20">20</xref>]. In fact, our data did not show differences in nuclear telomerase activity between patient arms. Mitochondrial TERT appears to influence mitochondrial biogenesis and metabolism, which is likely to affect survival of cells as well as a reduction in SASP characterised by secretion of pro-inflammatory cytokines. Acute and chronic inflammation lead to retainment of lymphocytes in either lymphatic tissues, adherence to endothelium in venous circulation, or transmigration to inflamed tissues [<xref ref-type="bibr" rid="CR33">33</xref>]. Reduced inflammation may therefore independently contribute to a higher number of lymphocytes in the circulation.</p>
              </sec>
              <sec id="Sec26">
                <title>Inflammation as a residual risk post ACS</title>
                <p id="Par35">Secondary prevention in patients who have undergone revascularisation after myocardial infarction aims to reduce their residual risk, predominantly by targeting hypercholesterolemia (with cholesterol-lowering agents) and platelet aggregation (with antiplatelet therapy). Recently, inflammation, as quantified by hsCRP, has been added to these determinants of residual risk. The CANTOS trial demonstrated that reducing inflammation in patients with coronary artery disease and elevated hsCRP (&gt; 2 mg/l) reduced the rate of major adverse cardiovascular events [<xref ref-type="bibr" rid="CR34">34</xref>]. In a more detailed subanalysis of the CANTOS trial, the authors found that the relative reduction in cardiovascular event rate was greatest in patients with the greatest on-treatment reduction in hsCRP [<xref ref-type="bibr" rid="CR35">35</xref>]. Interestingly, a reduction in hsCRP to below 1.8 mg/L reclassified patients into a lower risk group. In the TACTIC trial, we observed that the average hsCRP in our placebo group at 12 months was 2.9 mg/L, which could be considered as high risk, but was 62% lower in those treated with TA-65, at 1.1 mg/L, which would be low risk. The treatment effect was not statistically significant as the trial was not powered to detect a difference in hsCRP and there was a large variability of hsCRP in the acute phase of MI. The reduction in hsCRP with TA-65 was even more pronounced in STEMI patients, at 72%. Reducing inflammation after myocardial infarction is expected to yield benefit in two major ways. Firstly, myocardial infarction has been shown to accelerate the progression of coronary atherosclerosis even in the non-culprit artery, possibly through focal arterial inflammation, and reducing inflammation is expected to delay this process [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Secondly, adverse LV remodelling is propagated by excessive inflammation, and early studies with the IL-1 antagonist anakinra following MI suggest a reduction in incidence of heart failure [<xref ref-type="bibr" rid="CR38">38</xref>]. In the TACTIC trial, NT-proBNP was lower in the TA-65 group after 12 months (299 vs 520 pg/mL), but the treatment effect was not statistically significant.</p>
                <p id="Par36">The major limitation of canakinumab in the CANTOS trial was the effect of IL-1β blockade on immunity. Patients in the treatment group had more infections, and a higher risk of dying from sepsis. However, our data shows that patients treated with TA-65 have no significant change in myeloid cells (monocytes and neutrophils) compared to placebo, suggesting they do not have impaired innate immunity. Indeed, their adaptive immunity appears to be enhanced, as indicated by an increase in the number of all lymphocyte subsets. An increase in lymphocyte count from 1600 to 1900 cells/µL (similar to what we have observed with TA-65 treatment in this study) correlates with a 50% reduction in the hazard ratio for both all-cause mortality and cardiovascular mortality in the large JAMA cohort study of 50,000 healthy Americans [<xref ref-type="bibr" rid="CR9">9</xref>].</p>
                <p id="Par37">In summary, the telomerase activator TA-65 appears to enhance adaptive immune cell numbers in the peripheral blood without negatively affecting innate immunity. We observed a trend towards reduced inflammation in patients following MI, and we hypothesise based on work by other groups that improved mitochondrial function in T lymphocytes leads to a reduction in cytokine generation and hence reduced inflammation. Clinically, there was no evidence for an increase in adverse events with TA-65 – in fact there were significantly fewer adverse events in the TA-65 group.</p>
              </sec>
            </sec>
            <sec id="Sec27">
              <title>Limitations</title>
              <p id="Par38">Our trial did not have an age matched healthy control. It is not clear whether TA-65 preserves lymphocyte count for the age group or accelerates its return to normal after MI. While a reduction in hsCRP is demonstrated, measurement of systemic cytokine levels is needed to elucidate the impact of TA-65 on SASP. We used the Becton Dickinson 6-colour Trucount assay which has premixed antibodies that have been tested vigorously in clinical settings. It only comes with CD16, and not CD14. This limits our interpretation of monocyte subtypes as CD16 alone is not a fully reliable marker to distinguish intermediate, non-classical and classical monocytes. The mechanism of TA-65 remains unexplained. We plan to explore potential mechanisms in future studies by measuring telomere DNA length and mitochondrial functional assays in stored PMBC samples. Finally, the effects of TA-65 on lymphocyte count elevation and hsCRP reduction warrant an adequately powered study.</p>
            </sec>
            <sec id="Sec28">
              <title>Conclusion</title>
              <p id="Par39">Our pilot trial suggests that activation of telomerase could be a promising new drug target for patients following MI. Given the significant findings in lymphocyte increase, the trend in hsCRP reduction, as well as the extremely favourable safety profile, we propose as a next step a larger phase II clinical trial with multiple centres. We would set out to confirm whether one-year treatment with TA-65 following myocardial infarction can reduce hsCRP, shifting patients from a high to a low risk inflammatory profile.
</p>
            </sec>
            <sec sec-type="supplementary-material">
              <sec id="Sec29">
                <title>Supplementary Information</title>
                <p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11357_2023_794_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 11827 KB)</p></caption></media></supplementary-material></p>
              </sec>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations:</title>
              <def-list>
                <def-item>
                  <term>CABG</term>
                  <def>
                    <p id="Par2">Coronary artery bypass graft</p>
                  </def>
                </def-item>
                <def-item>
                  <term>MI</term>
                  <def>
                    <p id="Par3">Myocardial infarction</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PAT</term>
                  <def>
                    <p id="Par4">Peripheral arterial tone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>PCI</term>
                  <def>
                    <p id="Par5">Percutaneous coronary intervention</p>
                  </def>
                </def-item>
                <def-item>
                  <term>RHI</term>
                  <def>
                    <p id="Par6">Reactive hyperaemia index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>STEMI</term>
                  <def>
                    <p id="Par7">ST segment elevation myocardial infarction</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TERT</term>
                  <def>
                    <p id="Par8">Telomerase reverse transcriptase</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The trial was funded by TA-Sciences Inc (New York, US) as an investigator-led grant to I.S.</p>
              <p>BK is supported by a British Heart Foundation personal chair (CH//13/2/30154). K. Stellos is supported by grants from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (MODVASC, grant agreement No 759248) and the German Research Foundation DFG (SFB834 B12, project number 75732319).</p>
            </ack>
            <notes notes-type="data-availability">
              <title>Data availability</title>
              <p>Data are available upon request and following approval by the trial steering committee.</p>
            </notes>
            <notes>
              <title>Declarations</title>
              <notes id="FPar1" notes-type="COI-statement">
                <title>Conflict of interest</title>
                <p id="Par40">The authors declare no competing interests.</p>
              </notes>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <mixed-citation publication-type="other">Coelho-Lima J, Georgiopoulos G, Ahmed J, Adil SER, Gaskin D, Bakogiannis C, et al. Prognostic value of admission high-sensitivity troponin in patients with ST-elevation myocardial infarction. Heart. 2021;107:1881–8.</mixed-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stamatelopoulos</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Mueller-Hennessen</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Georgiopoulos</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Sachse</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Boeddinghaus</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Sopova</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Gatsiou</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Amrhein</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Biener</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Vafaie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Athanasouli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Stakos</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Pateras</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Twerenbold</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Badertscher</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Nestelberger</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Dimmeler</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Katus</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Zeiher</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Mueller</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Giannitsis</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Stellos</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Amyloid-β (1–40) and Mortality in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: A Cohort Study</article-title>
                  <source>Ann Intern Med</source>
                  <year>2018</year>
                  <volume>168</volume>
                  <fpage>855</fpage>
                  <lpage>865</lpage>
                  <pub-id pub-id-type="doi">10.7326/M17-1540</pub-id>
                  <?supplied-pmid 29799975?>
                  <pub-id pub-id-type="pmid">29799975</pub-id>
                </element-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spray</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Park</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Cormack</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mohammed</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Panahi</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Boag</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bennaceur</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Sopova</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Stangl</surname>
                      <given-names>VM</given-names>
                    </name>
                    <name>
                      <surname>Rech</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Rainer</surname>
                      <given-names>PP</given-names>
                    </name>
                    <name>
                      <surname>Ramos</surname>
                      <given-names>GC</given-names>
                    </name>
                    <name>
                      <surname>Hofmann</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Stellos</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>The Fractalkine Receptor CX<sub>3</sub>CR1 Links Lymphocyte Kinetics in CMV-Seropositive Patients and Acute Myocardial Infarction With Adverse Left Ventricular Remodeling</article-title>
                  <source>Front Immunol</source>
                  <year>2021</year>
                  <volume>12</volume>
                  <fpage>605857</fpage>
                  <pub-id pub-id-type="doi">10.3389/fimmu.2021.605857</pub-id>
                  <?supplied-pmid 34046028?>
                  <pub-id pub-id-type="pmid">34046028</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Boag</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Das</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Shmeleva</surname>
                      <given-names>EV</given-names>
                    </name>
                    <name>
                      <surname>Bagnall</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Egred</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Howard</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Bennaceur</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Zaman</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Keavney</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>T lymphocytes and fractalkine contribute to myocardial ischemia/reperfusion injury in patients</article-title>
                  <source>J Clin Invest</source>
                  <year>2015</year>
                  <volume>125</volume>
                  <fpage>3063</fpage>
                  <lpage>3076</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI80055</pub-id>
                  <?supplied-pmid 26168217?>
                  <pub-id pub-id-type="pmid">26168217</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Müller</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Fülöp</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Pawelec</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <article-title>Immunosenescence in vertebrates and invertebrates</article-title>
                  <source>Immun Ageing</source>
                  <year>2013</year>
                  <volume>10</volume>
                  <fpage>12</fpage>
                  <pub-id pub-id-type="doi">10.1186/1742-4933-10-12</pub-id>
                  <?supplied-pmid 23547999?>
                  <pub-id pub-id-type="pmid">23547999</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nikolich-Žugich</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Author Correction: The twilight of immunity: emerging concepts in aging of the immune system</article-title>
                  <source>Nat Immunol</source>
                  <year>2018</year>
                  <volume>19</volume>
                  <fpage>1146</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41590-018-0205-0</pub-id>
                  <?supplied-pmid 30177814?>
                  <pub-id pub-id-type="pmid">30177814</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Strindhall</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Nilsson</surname>
                      <given-names>BO</given-names>
                    </name>
                    <name>
                      <surname>Lofgren</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ernerudh</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Pawelec</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Johansson</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Wikby</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study</article-title>
                  <source>Exp Gerontol</source>
                  <year>2007</year>
                  <volume>42</volume>
                  <fpage>753</fpage>
                  <lpage>761</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.exger.2007.05.001</pub-id>
                  <?supplied-pmid 17606347?>
                  <pub-id pub-id-type="pmid">17606347</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alpert</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Pickman</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Leipold</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rosenberg-Hasson</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Ji</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Gaujoux</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Rabani</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Starosvetsky</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Kveler</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Schaffert</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Furman</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Caspi</surname>
                      <given-names>O</given-names>
                    </name>
                    <name>
                      <surname>Rosenschein</surname>
                      <given-names>U</given-names>
                    </name>
                    <name>
                      <surname>Khatri</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Dekker</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Maecker</surname>
                      <given-names>HT</given-names>
                    </name>
                    <name>
                      <surname>Davis</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Shen-Orr</surname>
                      <given-names>SS</given-names>
                    </name>
                  </person-group>
                  <article-title>A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring</article-title>
                  <source>Nat Med</source>
                  <year>2019</year>
                  <volume>25</volume>
                  <fpage>487</fpage>
                  <lpage>495</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41591-019-0381-y</pub-id>
                  <?supplied-pmid 30842675?>
                  <pub-id pub-id-type="pmid">30842675</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Zidar</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Al-Kindi</surname>
                      <given-names>SG</given-names>
                    </name>
                    <name>
                      <surname>Liu</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Krieger</surname>
                      <given-names>NI</given-names>
                    </name>
                    <name>
                      <surname>Perzynski</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Osnard</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Nmai</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Anthony</surname>
                      <given-names>DD</given-names>
                    </name>
                    <name>
                      <surname>Lederman</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Freeman</surname>
                      <given-names>ML</given-names>
                    </name>
                    <name>
                      <surname>Bonomo</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Simon</surname>
                      <given-names>DI</given-names>
                    </name>
                    <name>
                      <surname>Dalton</surname>
                      <given-names>JE</given-names>
                    </name>
                  </person-group>
                  <article-title>Association of Lymphopenia With Risk of Mortality Among Adults in the US General Population</article-title>
                  <source>JAMA Netw Open</source>
                  <year>2019</year>
                  <volume>2</volume>
                  <fpage>e1916526</fpage>
                  <pub-id pub-id-type="doi">10.1001/jamanetworkopen.2019.16526</pub-id>
                  <?supplied-pmid 31790569?>
                  <pub-id pub-id-type="pmid">31790569</pub-id>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Martin-Ruiz</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shmeleva</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Zglinicki</surname>
                      <given-names>TV</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Draganova</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Redgrave</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Collerton</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Arthur</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Keavney</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>CMV-independent increase in CD27-CD28+ CD8+ EMRA T cells is inversely related to mortality in octogenarians</article-title>
                  <source>NPJ Aging Mech Dis</source>
                  <year>2020</year>
                  <volume>6</volume>
                  <fpage>3</fpage>
                  <pub-id pub-id-type="doi">10.1038/s41514-019-0041-y</pub-id>
                  <?supplied-pmid 31993214?>
                  <pub-id pub-id-type="pmid">31993214</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Martin-Ruiz</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Hilkens</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Yadegarfar</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Isaacs</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Jagger</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Kirkwood</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>von Zglinicki</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>CMV seropositivity and T-cell senescence predict increased cardiovascular mortality in octogenarians: results from the Newcastle 85+ study</article-title>
                  <source>Aging Cell</source>
                  <year>2016</year>
                  <volume>15</volume>
                  <fpage>389</fpage>
                  <lpage>392</lpage>
                  <pub-id pub-id-type="doi">10.1111/acel.12430</pub-id>
                  <?supplied-pmid 26696322?>
                  <pub-id pub-id-type="pmid">26696322</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Shmeleva</surname>
                      <given-names>EV</given-names>
                    </name>
                    <name>
                      <surname>Boag</surname>
                      <given-names>SE</given-names>
                    </name>
                    <name>
                      <surname>Fiser</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Bagnall</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Murali</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Dimmick</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Pircher</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Martin-Ruiz</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Egred</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Keavney</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>von Zglinicki</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Das</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Todryk</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Myocardial Ischemia and Reperfusion Leads to Transient CD8 Immune Deficiency and Accelerated Immunosenescence in CMV-Seropositive Patients</article-title>
                  <source>Circ Res</source>
                  <year>2015</year>
                  <volume>116</volume>
                  <fpage>87</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.304393</pub-id>
                  <?supplied-pmid 25385851?>
                  <pub-id pub-id-type="pmid">25385851</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Aicher</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Brummendorf</surname>
                      <given-names>TH</given-names>
                    </name>
                    <name>
                      <surname>Doerr</surname>
                      <given-names>HW</given-names>
                    </name>
                    <name>
                      <surname>Zeiher</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Dimmeler</surname>
                      <given-names>S</given-names>
                    </name>
                  </person-group>
                  <article-title>Accelerated telomere shortening in leukocyte subpopulations of patients with coronary heart disease: role of cytomegalovirus seropositivity</article-title>
                  <source>Circulation</source>
                  <year>2009</year>
                  <volume>120</volume>
                  <fpage>1364</fpage>
                  <lpage>1372</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.854299</pub-id>
                  <?supplied-pmid 19770396?>
                  <pub-id pub-id-type="pmid">19770396</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Olovnikov</surname>
                      <given-names>AM</given-names>
                    </name>
                  </person-group>
                  <article-title>A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon</article-title>
                  <source>J Theor Biol</source>
                  <year>1973</year>
                  <volume>41</volume>
                  <fpage>181</fpage>
                  <lpage>190</lpage>
                  <pub-id pub-id-type="doi">10.1016/0022-5193(73)90198-7</pub-id>
                  <?supplied-pmid 4754905?>
                  <pub-id pub-id-type="pmid">4754905</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Beyer</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Freed</surname>
                      <given-names>JK</given-names>
                    </name>
                    <name>
                      <surname>Durand</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Riedel</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ait-Aissa</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Hockenberry</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Morgan</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>Donato</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Peleg</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Gasparri</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rokkas</surname>
                      <given-names>CK</given-names>
                    </name>
                    <name>
                      <surname>Santos</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Priel</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Gutterman</surname>
                      <given-names>DD</given-names>
                    </name>
                  </person-group>
                  <article-title>Critical Role for Telomerase in the Mechanism of Flow-Mediated Dilation in the Human Microcirculation</article-title>
                  <source>Circ Res</source>
                  <year>2016</year>
                  <volume>118</volume>
                  <fpage>856</fpage>
                  <lpage>866</lpage>
                  <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.307918</pub-id>
                  <?supplied-pmid 26699654?>
                  <pub-id pub-id-type="pmid">26699654</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richardson</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Sage</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Bennaceur</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Al Zhrany</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Coelho-Lima</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Dookun</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Draganova</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Saretzki</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Breault</surname>
                      <given-names>DT</given-names>
                    </name>
                    <name>
                      <surname>Mallat</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Telomerase Mediates Lymphocyte Proliferation but Not the Atherosclerosis-Suppressive Potential of Regulatory T-Cells</article-title>
                  <source>Arterioscler Thromb Vasc Biol</source>
                  <year>2018</year>
                  <volume>38</volume>
                  <fpage>1283</fpage>
                  <lpage>1296</lpage>
                  <pub-id pub-id-type="doi">10.1161/ATVBAHA.117.309940</pub-id>
                  <?supplied-pmid 29599138?>
                  <pub-id pub-id-type="pmid">29599138</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <mixed-citation publication-type="other">Ale-Agha N, Jakobs P, Goy C, Zurek M, Rosen J, Dyballa-Rukes N, et al. Mitochondrial telomerase reverse transcriptase protects from myocardial ischemia/reperfusion injury by improving complex I composition and function. Circulation. 2021;144:1876–90.</mixed-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Herbert</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Hochreiter</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Wright</surname>
                      <given-names>WE</given-names>
                    </name>
                    <name>
                      <surname>Shay</surname>
                      <given-names>JW</given-names>
                    </name>
                  </person-group>
                  <article-title>Nonradioactive detection of telomerase activity using the telomeric repeat amplification protocol</article-title>
                  <source>Nat Protoc</source>
                  <year>2006</year>
                  <volume>1</volume>
                  <fpage>1583</fpage>
                  <lpage>1590</lpage>
                  <pub-id pub-id-type="doi">10.1038/nprot.2006.239</pub-id>
                  <?supplied-pmid 17406450?>
                  <pub-id pub-id-type="pmid">17406450</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Verma</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Ogonek</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Varanasi</surname>
                      <given-names>PR</given-names>
                    </name>
                    <name>
                      <surname>Luther</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Bünting</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Thomay</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Behrens</surname>
                      <given-names>YL</given-names>
                    </name>
                    <name>
                      <surname>Mischak-Weissinger</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Hambach</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Human CD8+ CD57- TEMRA cells: Too young to be called “old”</article-title>
                  <source>PLoS ONE</source>
                  <year>2017</year>
                  <volume>12</volume>
                  <fpage>e0177405</fpage>
                  <pub-id pub-id-type="doi">10.1371/journal.pone.0177405</pub-id>
                  <?supplied-pmid 28481945?>
                  <pub-id pub-id-type="pmid">28481945</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Passos</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Saretzki</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>von Zglinicki</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>DNA damage in telomeres and mitochondria during cellular senescence: is there a connection?</article-title>
                  <source>Nucleic Acids Res</source>
                  <year>2007</year>
                  <volume>35</volume>
                  <fpage>7505</fpage>
                  <lpage>7513</lpage>
                  <pub-id pub-id-type="doi">10.1093/nar/gkm893</pub-id>
                  <?supplied-pmid 17986462?>
                  <pub-id pub-id-type="pmid">17986462</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ron-Harel</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Notarangelo</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Ghergurovich</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Paulo</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Sage</surname>
                      <given-names>PT</given-names>
                    </name>
                    <name>
                      <surname>Santos</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Satterstrom</surname>
                      <given-names>FK</given-names>
                    </name>
                    <name>
                      <surname>Gygi</surname>
                      <given-names>SP</given-names>
                    </name>
                    <name>
                      <surname>Rabinowitz</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Sharpe</surname>
                      <given-names>AH</given-names>
                    </name>
                    <name>
                      <surname>Haigis</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Defective respiration and one-carbon metabolism contribute to impaired naïve T cell activation in aged mice</article-title>
                  <source>Proc Natl Acad Sci U S A</source>
                  <year>2018</year>
                  <volume>115</volume>
                  <fpage>13347</fpage>
                  <lpage>13352</lpage>
                  <pub-id pub-id-type="doi">10.1073/pnas.1804149115</pub-id>
                  <?supplied-pmid 30530686?>
                  <pub-id pub-id-type="pmid">30530686</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Callender</surname>
                      <given-names>LA</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>EC</given-names>
                    </name>
                    <name>
                      <surname>Bober</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Akbar</surname>
                      <given-names>AN</given-names>
                    </name>
                    <name>
                      <surname>Solito</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Henson</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Mitochondrial mass governs the extent of human T cell senescence</article-title>
                  <source>Aging Cell</source>
                  <year>2020</year>
                  <volume>19</volume>
                  <fpage>e13067</fpage>
                  <pub-id pub-id-type="doi">10.1111/acel.13067</pub-id>
                  <?supplied-pmid 31788930?>
                  <pub-id pub-id-type="pmid">31788930</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Desdín-Micó</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Soto-Heredero</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Aranda</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Oller</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Carrasco</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Gabandé-Rodríguez</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Blanco</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Alfranca</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Cussó</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Desco</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ibañez</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Gortazar</surname>
                      <given-names>AR</given-names>
                    </name>
                    <name>
                      <surname>Fernández-Marcos</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Navarro</surname>
                      <given-names>MN</given-names>
                    </name>
                    <name>
                      <surname>Hernaez</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Alcamí</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Baixauli</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Mittelbrunn</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>T cells with dysfunctional mitochondria induce multimorbidity and premature senescence</article-title>
                  <source>Science</source>
                  <year>2020</year>
                  <volume>368</volume>
                  <fpage>1371</fpage>
                  <lpage>1376</lpage>
                  <pub-id pub-id-type="doi">10.1126/science.aax0860</pub-id>
                  <?supplied-pmid 32439659?>
                  <pub-id pub-id-type="pmid">32439659</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Owens</surname>
                      <given-names>WA</given-names>
                    </name>
                    <name>
                      <surname>Walaszczyk</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Dookun</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>GD</given-names>
                    </name>
                  </person-group>
                  <article-title>Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls</article-title>
                  <source>Mech Ageing Dev</source>
                  <year>2021</year>
                  <volume>198</volume>
                  <fpage>111540</fpage>
                  <pub-id pub-id-type="doi">10.1016/j.mad.2021.111540</pub-id>
                  <?supplied-pmid 34237321?>
                  <pub-id pub-id-type="pmid">34237321</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <mixed-citation publication-type="other">Dookun E, Passos JF, Arthur HM, Richardson GD. Therapeutic potential of senolytics in cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:187–96.</mixed-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <mixed-citation publication-type="other">Dookun E, Walaszczyk A, Redgrave R, Palmowski P, Tual-Chalot S, Suwana A, Chapman J, Jirkovsky E, Donastorg Sosa L, Gill E, Yausep OE, Santin Y, Mialet-Perez J, Andrew Owens W, Grieve D, Spyridopoulos I, Taggart M, Arthur HM, Passos JF, Richardson GD. Clearance of senescent cells during cardiac ischemia-reperfusion injury improves recovery. Aging Cell. 2020:e13249.</mixed-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walaszczyk</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Dookun</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Redgrave</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Tual-Chalot</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Victorelli</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Owens</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Arthur</surname>
                      <given-names>HM</given-names>
                    </name>
                    <name>
                      <surname>Passos</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>GD</given-names>
                    </name>
                  </person-group>
                  <article-title>Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction</article-title>
                  <source>Aging Cell</source>
                  <year>2019</year>
                  <volume>18</volume>
                  <fpage>e12945</fpage>
                  <pub-id pub-id-type="doi">10.1111/acel.12945</pub-id>
                  <?supplied-pmid 30920115?>
                  <pub-id pub-id-type="pmid">30920115</pub-id>
                </element-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Correia-Melo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Marques</surname>
                      <given-names>FD</given-names>
                    </name>
                    <name>
                      <surname>Anderson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hewitt</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Hewitt</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Cole</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Carroll</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Miwa</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Birch</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Merz</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rushton</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Charles</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Jurk</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Tait</surname>
                      <given-names>SW</given-names>
                    </name>
                    <name>
                      <surname>Czapiewski</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Greaves</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Nelson</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Bohlooly-Y</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rodriguez-Cuenca</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Vidal-Puig</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Saretzki</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Quarato</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Green</surname>
                      <given-names>DR</given-names>
                    </name>
                    <name>
                      <surname>Adams</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>von Zglinicki</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Korolchuk</surname>
                      <given-names>VI</given-names>
                    </name>
                    <name>
                      <surname>Passos</surname>
                      <given-names>JF</given-names>
                    </name>
                  </person-group>
                  <article-title>Mitochondria are required for pro-ageing features of the senescent phenotype</article-title>
                  <source>EMBO J</source>
                  <year>2016</year>
                  <volume>35</volume>
                  <fpage>724</fpage>
                  <lpage>742</lpage>
                  <pub-id pub-id-type="doi">10.15252/embj.201592862</pub-id>
                  <?supplied-pmid 26848154?>
                  <pub-id pub-id-type="pmid">26848154</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yuan</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Larsson</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Xu</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players</article-title>
                  <source>Oncogene</source>
                  <year>2019</year>
                  <volume>38</volume>
                  <fpage>6172</fpage>
                  <lpage>6183</lpage>
                  <pub-id pub-id-type="doi">10.1038/s41388-019-0872-9</pub-id>
                  <?supplied-pmid 31285550?>
                  <pub-id pub-id-type="pmid">31285550</pub-id>
                </element-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hoffmann</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Haendeler</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Altschmied</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Andrés</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Spyridopoulos</surname>
                      <given-names>I</given-names>
                    </name>
                  </person-group>
                  <article-title>Telomerase as a Therapeutic Target in Cardiovascular Disease</article-title>
                  <source>Arterioscler Thromb Vasc Biol</source>
                  <year>2021</year>
                  <volume>41</volume>
                  <fpage>1047</fpage>
                  <lpage>1061</lpage>
                  <pub-id pub-id-type="doi">10.1161/ATVBAHA.120.315695</pub-id>
                  <?supplied-pmid 33504179?>
                  <pub-id pub-id-type="pmid">33504179</pub-id>
                </element-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mallat</surname>
                      <given-names>Z</given-names>
                    </name>
                  </person-group>
                  <article-title>Regulating heart repair with cardiac-specific T lymphocytes</article-title>
                  <source>J Clin Invest</source>
                  <year>2019</year>
                  <volume>129</volume>
                  <fpage>4587</fpage>
                  <lpage>4589</lpage>
                  <pub-id pub-id-type="doi">10.1172/JCI132441</pub-id>
                  <?supplied-pmid 31609249?>
                  <pub-id pub-id-type="pmid">31609249</pub-id>
                </element-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ferrer-Font</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Pellefigues</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Mayer</surname>
                      <given-names>JU</given-names>
                    </name>
                    <name>
                      <surname>Small</surname>
                      <given-names>SJ</given-names>
                    </name>
                    <name>
                      <surname>Jaimes</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Price</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>Panel Design and Optimization for High-Dimensional Immunophenotyping Assays Using Spectral Flow Cytometry</article-title>
                  <source>Curr Protoc Cytom</source>
                  <year>2020</year>
                  <volume>92</volume>
                  <fpage>e70</fpage>
                  <pub-id pub-id-type="doi">10.1002/cpcy.70</pub-id>
                  <?supplied-pmid 32150355?>
                  <pub-id pub-id-type="pmid">32150355</pub-id>
                </element-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Buonacera</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Stancanelli</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Colaci</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Malatino</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Neutrophil to Lymphocyte Ratio: An Emerging Marker of the Relationships between the Immune System and Diseases</article-title>
                  <source>Int J Mol Sci</source>
                  <year>2022</year>
                  <volume>23</volume>
                  <fpage>3636</fpage>
                  <pub-id pub-id-type="doi">10.3390/ijms23073636</pub-id>
                  <?supplied-pmid 35408994?>
                  <pub-id pub-id-type="pmid">35408994</pub-id>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ridker</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>Everett</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Thuren</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>MacFadyen</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Chang</surname>
                      <given-names>WH</given-names>
                    </name>
                    <name>
                      <surname>Ballantyne</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Fonseca</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Nicolau</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Koenig</surname>
                      <given-names>W</given-names>
                    </name>
                    <name>
                      <surname>Anker</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Kastelein</surname>
                      <given-names>JJP</given-names>
                    </name>
                    <name>
                      <surname>Cornel</surname>
                      <given-names>JH</given-names>
                    </name>
                    <name>
                      <surname>Pais</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Pella</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Genest</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Cifkova</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lorenzatti</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Forster</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kobalava</surname>
                      <given-names>Z</given-names>
                    </name>
                    <name>
                      <surname>Vida-Simiti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Flather</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Shimokawa</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Ogawa</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Dellborg</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Rossi</surname>
                      <given-names>PRF</given-names>
                    </name>
                    <name>
                      <surname>Troquay</surname>
                      <given-names>RPT</given-names>
                    </name>
                    <name>
                      <surname>Libby</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Glynn</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>CANTOS TG. </surname>
                    </name>
                  </person-group>
                  <article-title>Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease</article-title>
                  <source>N Engl J Med</source>
                  <year>2017</year>
                  <volume>377</volume>
                  <fpage>1119</fpage>
                  <lpage>1131</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1707914</pub-id>
                  <?supplied-pmid 28845751?>
                  <pub-id pub-id-type="pmid">28845751</pub-id>
                </element-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ridker</surname>
                      <given-names>PM</given-names>
                    </name>
                    <name>
                      <surname>MacFadyen</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Everett</surname>
                      <given-names>BM</given-names>
                    </name>
                    <name>
                      <surname>Libby</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Thuren</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Glynn</surname>
                      <given-names>RJ</given-names>
                    </name>
                    <name>
                      <surname>CANTOS TG. </surname>
                    </name>
                  </person-group>
                  <article-title>Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial</article-title>
                  <source>Lancet</source>
                  <year>2018</year>
                  <volume>391</volume>
                  <fpage>319</fpage>
                  <lpage>328</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0140-6736(17)32814-3</pub-id>
                  <?supplied-pmid 29146124?>
                  <pub-id pub-id-type="pmid">29146124</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dutta</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Courties</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>Wei</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Leuschner</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Gorbatov</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Robbins</surname>
                      <given-names>CS</given-names>
                    </name>
                    <name>
                      <surname>Iwamoto</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Carlson</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Heidt</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Majmudar</surname>
                      <given-names>MD</given-names>
                    </name>
                    <name>
                      <surname>Lasitschka</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Etzrodt</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Waterman</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Waring</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Chicoine</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>van der Laan</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Niessen</surname>
                      <given-names>HW</given-names>
                    </name>
                    <name>
                      <surname>Piek</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Rubin</surname>
                      <given-names>BB</given-names>
                    </name>
                    <name>
                      <surname>Butany</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Stone</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Katus</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Morrow</surname>
                      <given-names>DA</given-names>
                    </name>
                    <name>
                      <surname>Sabatine</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Vinegoni</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Moskowitz</surname>
                      <given-names>MA</given-names>
                    </name>
                    <name>
                      <surname>Pittet</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Libby</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Lin</surname>
                      <given-names>CP</given-names>
                    </name>
                    <name>
                      <surname>Swirski</surname>
                      <given-names>FK</given-names>
                    </name>
                    <name>
                      <surname>Weissleder</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Nahrendorf</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Myocardial infarction accelerates atherosclerosis</article-title>
                  <source>Nature</source>
                  <year>2012</year>
                  <volume>487</volume>
                  <fpage>325</fpage>
                  <lpage>329</lpage>
                  <pub-id pub-id-type="doi">10.1038/nature11260</pub-id>
                  <?supplied-pmid 22763456?>
                  <pub-id pub-id-type="pmid">22763456</pub-id>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lavin Plaza</surname>
                      <given-names>B</given-names>
                    </name>
                    <name>
                      <surname>Phinikaridou</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Andia</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Potter</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Lorrio</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Rashid</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Botnar</surname>
                      <given-names>RM</given-names>
                    </name>
                  </person-group>
                  <article-title>Sustained Focal Vascular Inflammation Accelerates Atherosclerosis in Remote Arteries</article-title>
                  <source>Arterioscler Thromb Vasc Biol</source>
                  <year>2020</year>
                  <volume>40</volume>
                  <fpage>2159</fpage>
                  <lpage>2170</lpage>
                  <pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314387</pub-id>
                  <?supplied-pmid 32673527?>
                  <pub-id pub-id-type="pmid">32673527</pub-id>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <mixed-citation publication-type="other">Abbate A, Wohlford GF, Del Buono MG, Chiabrando JG, Markley R, Turlington J, et al. Interleukin-1 blockade with Anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials. Eur Heart J Cardiovasc Pharmacother. 2022;11:503–10.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
